Literature DB >> 7843430

Gonadotropin requirements of the developing follicle.

K A Thompson1, P S LaPolt, J River, G Henderson, K D Dahl, D R Meldrum.   

Abstract

OBJECTIVE: To evaluate follicular FSH and LH requirements during suppression of endogenous gonadotropins with the GnRH antagonist Nal-Glu and whether LH-like activity could be supplied by administering subcutaneous hCG.
DESIGN: Randomized clinical trial. PARTICIPANTS: Thirty-two normally cycling females in the late follicular phase (dominant follicle mean diameter > or = 14 mm). INTERVENTION: Twelve normal women were randomized to receive 150 IU IM FSH with or without 75 IU SC hCG; 11 subjects were randomized to receive 225 IU FSH with or without 50 IU SC hCG; 9 women received 150 or 225 IU IM hMG. Subjects returned the next day for repeat blood sample and ultrasound.
RESULTS: Continued follicular maturation, as evidenced by rising E2 levels, correlated with serum immunoactive and bioactive FSH levels and was unrelated to bioactive LH-hCG. Two hundred twenty-five international units of exogenous FSH consistently supported follicular maturation. There was a similar increase in mean follicular diameter in women with an E2 rise versus those with a plateau or fall. In subjects receiving SC mini-dose hCG, serum bioactive LH-hCG levels were increased significantly and were similar to levels before Nal-Glu.
CONCLUSIONS: During administration of a GnRH-a, the maturing follicle appears to require only FSH support. In markedly hypogonadotropic women, mini-dose hCG may be a more practical alternative to recombinant LH to promote normal follicle maturation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843430

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

Review 1.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

Authors:  R Felberbaum; T Reissmann; W Küpker; S Al-Hasani; O Bauer; T Schill; C Zoll; C Diedrich; K Diedrich
Journal:  J Assist Reprod Genet       Date:  1996-03       Impact factor: 3.412

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.